CTP-15. Dordaviprone (ONC201) in a pediatric patient with recurrent H3 K27M-mutant diffuse glioma and leptomeningeal disease
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.0587
Abstract: H3 K27M-mutant diffuse midline glioma (DMG) is a molecularly and clinically distinct subtype of CNS WHO Grade 4 glioma with a median overall survival (mOS) of ~1 year from diagnosis. Leptomeningeal disease (LMD) has been… read more here.
Keywords: dordaviprone; mutant diffuse; k27m; k27m mutant ... See more keywords
Abstract CT060: ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct060
Abstract: Background: H3 K27M-mutant diffuse midline glioma is a universally fatal malignancy primarily affecting children and young adults. While radiotherapy (RT) provides transient benefit, no effective systemic therapy is currently available and current standard of care… read more here.
Keywords: mutant diffuse; k27m mutant; glioma; dordaviprone ... See more keywords
Abstract 361: Allosteric ClpP agonist ONC206 alters mitochondrial metabolism, stress response, chromatin accessibility and cell cycle to elicit apoptosis in pheochromocytoma
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-361
Abstract: Dordaviprone (ONC201), an allosteric caseinolytic protease P (ClpP) agonist and dopamine receptor D2/3 (DRD2/3) antagonist, has demonstrated durable responses in recurrent H3 K27M-mutant glioma patients. ONC206, a derivative of dordaviprone with nanomolar potency for DRD2/3… read more here.
Keywords: dordaviprone; response; clpp; cell ... See more keywords